The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Samuel Broder named executive VP at Intrexon Corporation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

SAMUEL BRODER was named executive vice president of scientific and public affairs at the Intrexon Corporation. The former director of NCI was most recently chairman of Intrexon’s health sector.

Broder will lead the company’s communications programs with media, academia, government, and non-profit organizations, spanning health, food, energy, environment, and consumer sectors.

YOU MAY BE INTERESTED IN

Black History MonthPodcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
By Robert A. Winn, Otis W. Brawley and Preston Willett
Capitol Hill

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 
By Jacquelyn Cobb

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account